TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12032722

Group type: EXPERIMENTAL
Intervention: Standard dose cyclosporine A (15 mg/kg/day for 2 days, 7.5 mg/kg/day for 2 days, then adjusted to maintain trough blood levels of 100-200 microg/l)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low dose cyclosporine A (2 mg/kg/day with no loading dose)
Number of subjects: 34
Study: 9661611

Group type: EXPERIMENTAL
Intervention: Heterozygous relatives (n=58)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Homozygous normal relatives (n=37)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Heterozygous relatives (n=33)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Homozygous normal relatives (n=29)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Parental height SDS of affected offspring
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Unaffected siblings (normals or carriers)
Number of subjects: 165
Study: 7650300

Group type: EXPERIMENTAL
Intervention: Geriatric orthopaedic nursing education program
Number of subjects: 26
Study: 2696890

Group type: EXPERIMENTAL
Intervention: Ceftazidime i.v. (2 g) in three doses (half an hour before surgery, 8 and 16 hours from the first dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Netilmicin (100 mg) plus clindamycin (600 mg i.v.), following the same chronological schedule
Number of subjects: 22
Study: 330290

Group type: EXPERIMENTAL
Intervention: Lentizol 50 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tryptizol 75 mg
Number of subjects: 50
Study: 31030773

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 182
Study: 29283612

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed treatment minimal contact control
Number of subjects: 67
Study: 25641533

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Bare-metal stents
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Target vessel revascularization (TVR)
Number of subjects: 3602
Study: 24060269

Group type: EXPERIMENTAL
Intervention: Acute low-intensity cycling for one hour at 50% of maximum oxygen uptake
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (three hours of rest)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute low-intensity cycling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute low-intensity exercise
Number of subjects: 30
Study: 21345470

Group type: EXPERIMENTAL
Intervention: Aerobic exercises + progressive relaxation techniques
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (sham treatment with disconnected magnet therapy device)
Number of subjects: 56
Study: 20031818

Group type: EXPERIMENTAL
Intervention: Preoperative coronary artery revascularization
Number of subjects: 462

Group type: COMPARATOR
Intervention: No preoperative revascularization
Number of subjects: 462
Study: 16860808

Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pravastatin 40mg/day
Number of subjects: 35
Study: 15118489

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10831175

Group type: EXPERIMENTAL
Intervention: Slow-release lanreotide (SR-L) 30 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (7 normal subjects)
Number of subjects: 7
Study: 9505983

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 to 80 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prednisolone (1.25 to 100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prednisolone (multiple doses)
Number of subjects: 24
Study: 8415211

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 31

Group type: COMPARATOR
Intervention: MC pork insulin
Number of subjects: 31
Study: 2937338

Group type: EXPERIMENTAL
Intervention: Alfentanil 8 micrograms kg‐1
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study: 31421583

Group type: EXPERIMENTAL
Intervention: Gamified PNF + Maximum Copresence
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Gamified PNF Only
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Gamified PNF + Visual Copresence
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard PNF
Number of subjects: 235
Study: 28615149

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 25956604

Group type: EXPERIMENTAL
Intervention: Motor practice (MP) - wrist extension‐flexion visuomotor skill for 20 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Attentional control (AC) - watched templates without movements (n = 11, mean age 70.5 years)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Corticospinal excitability during contraction at 20% of maximal force
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intracortical inhibition and facilitation metrics
Number of subjects: 11
Study: 22796996

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Contrast bath therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold water immersion and contrast bath therapy
Number of subjects: 24
Study: 21239049

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 26
Study: 17700579

Group type: EXPERIMENTAL
Intervention: Standard diet (omnivorous)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Vegetarian diet (lacto-ovo-vegetarian)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Diet of choice (standard)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Diet of choice (vegetarian)
Number of subjects: 176
Study: 16926578

Group type: EXPERIMENTAL
Intervention: Patients with nonspecific musculoskeletal disorders
Number of subjects: 78

Group type: COMPARATOR
Intervention: Matched control group of nonpatients
Number of subjects: 78
Study: 12574806

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UFH)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-molecular-weight heparin (reviparin) twice daily for one week
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Subcutaneous reviparin once daily for four weeks
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for at least 3 months
Number of subjects: 885

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 885
Study: 10501793

Group type: EXPERIMENTAL
Intervention: Calcium 1 g twice daily for 12 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcium 1 g twice daily for 12 months plus intranasal calcitonin 400 IU/day for the first month and then 200 IU/day for 11 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined groups (Calcium with or without calcitonin)
Number of subjects: 30
Study: 8832013

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose heparin (100 units/kg/day) from the first day of the preparative regimen to day +30 or until discharge.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (historical controls) receiving BMT for a variety of disorders, total of 70 patients.
Number of subjects: 50
Study: 1848167

Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Angiotensin II infusion (0.5 and 1.0 ng min-1 kg-1)
Number of subjects: 6
Study: 6353127

Group type: EXPERIMENTAL
Intervention: Physical conditioning group (8‐wk progressive aerobic exercise program, 30 min/d for 4 d each wk)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 30367457

Group type: EXPERIMENTAL
Intervention: Drug A at the optimal phase I‐II dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment C
Number of subjects: 0
Study: 29247172

Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg iron as ferrous fumarate daily)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Baseline (before supplementation)
Number of subjects: 327
Study: 26713821

Group type: EXPERIMENTAL
Intervention: Nutritional counselling with caloric restriction for 12 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional medical care alone
Number of subjects: 80
Study: 24864481

Group type: EXPERIMENTAL
Intervention: Underwater shower massage and electrical stimulation
Number of subjects: 120
Study: 22591506

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (plaster cast immobilization)
Number of subjects: 20
Study: 20450458

Group type: EXPERIMENTAL
Intervention: Chronic neck pain patients exerting to their 20% maximum voluntary contraction (MVC), pain threshold, and pain tolerance levels.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy controls exerting to their 20% MVC, 60% MVC, and MVC.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Wavelet decomposition with principal component analysis at 20% MVC.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Wavelet decomposition with principal component analysis at pain threshold/60% MVC.
Number of subjects: 67
Study: 17322539

Group type: EXPERIMENTAL
Intervention: pemetrexed 500 mg/m(2)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2)
Number of subjects: 571

Group type: COMPARATOR
Intervention: first-line therapy types (gemcitabine + platinum, taxane + platinum, other therapies)
Number of subjects: 571
Study: 15803358

Group type: EXPERIMENTAL
Intervention: Clodronate treatment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study: 12225716

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (Adizem XL) 300 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine/atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem (Adizem XL)/isosorbide 5‐mononitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine/atenolol during drug-free interval
Number of subjects: 0
Study: 10212715

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A5)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A10)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol 2.5 mg.kg‐1 only (Group P)
Number of subjects: 150
Study: 7600753

Group type: EXPERIMENTAL
Intervention: Structured teaching and treatment programme
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no programme)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 108
Study: 1516498

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment (n = 59)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nondiabetic participants
Number of subjects: 135
Study: 6337667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Emepronium bromide 200 mg qid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flavoxate chloride 200 mg qid
Number of subjects: 19
Study: 30782512

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 101
Study: 29735474

Group type: EXPERIMENTAL
Intervention: Multicomponent technology‐based intervention targeting adherence to daily controller medication (2 sessions of computer‐delivered motivational interviewing and individualized text messaging)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group receiving computer‐delivered asthma education modules and general text messages about asthma
Number of subjects: 192
Study: 25577741

Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24289574

Group type: EXPERIMENTAL
Intervention: Basant polyherbal vaginal cream
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Curcumin vaginal capsules
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo vaginal cream
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo vaginal capsules
Number of subjects: 287
Study: 21986570

Group type: EXPERIMENTAL
Intervention: Single dose of calcium L-threonate (675, 2025, or 4050 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repeated doses of calcium L-threonate (2025 mg twice daily for 4 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasted subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cumulative urinary excretion of L-threonate
Number of subjects: 24
Study: 19065098

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention for dementia caregivers, details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volunteer program, details on dosage and duration not available.
Number of subjects: 0
Study: 17068085

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model - Model A
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model - Model B
Number of subjects: 93
Study: 15307855

Group type: EXPERIMENTAL
Intervention: Exercise (60 min total: 30 min running and 30 min resistance exercises)
Number of subjects: 20
Study: 11558843

Group type: EXPERIMENTAL
Intervention: Oral slow-release isosorbide dinitrate (ISDN) 20 mg three times a day
Number of subjects: 1102

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1102
Study: 8822678

Group type: EXPERIMENTAL
Intervention: Older adults (55 years and older)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Younger adults (18 to 54 years old)
Number of subjects: 100
Study: 1448251

Group type: EXPERIMENTAL
Intervention: Pomeroy tubal ligation using endoloop sutures
Number of subjects: 53

Group type: COMPARATOR
Intervention: Laparoscopic tubal ligation with Silastic rings
Number of subjects: 53
Study: 3972221

Group type: EXPERIMENTAL
Intervention: Ileal infusion of Intralipid
Number of subjects: 5
Study: 30803843

Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus A71 vaccine, administered in two doses with a 28-day or 56-day interval, booster dose at one year for participants aged two months to <two years
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus A71 vaccine
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 29989868

Group type: EXPERIMENTAL
Intervention: 20 mg/day of chelated zinc gluconate for one month
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (diet rich in zinc only)
Number of subjects: 28
Study: 26645244

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS) combined with septorhinoplasty (SRP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Septorhinoplasty (SRP) alone
Number of subjects: 55
Study: 24925492

Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 151
Study: 22805391

Group type: EXPERIMENTAL
Intervention: 200 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20824151

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin and Fenofibrate) from weeks 12-48
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 17099309

Group type: EXPERIMENTAL
Intervention: Amuchina 10% solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: pH neutral soap
Number of subjects: 60
Study: 16225577

Group type: EXPERIMENTAL
Intervention: Diagnostic model based on patient history, pelvic examination, and validated questionnaire
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Prolapse of the posterior vaginal wall, history of abdominal or pelvic surgery, and presence of constipation
Number of subjects: 82
Study: 12396323

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of DEC (6 mg/kg) and Albendazole (400 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10546012

Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fasting HDL cholesterol
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fasting HDL2 cholesterol
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fasting HDL3 cholesterol
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fasting triglycerides
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 175
Study: 7597431

Group type: EXPERIMENTAL
Intervention: Paclitaxel 170 mg/m2 followed by ifosfamide 5 g/m2 divided over 3 days with mesna
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil
Number of subjects: 13
Study: 2142040

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 724875

Group type: EXPERIMENTAL
Intervention: Directive therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interpretative therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 42
Study: 29217959

Group type: EXPERIMENTAL
Intervention: 0.25% lemongrass oil mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral prophylaxis only
Number of subjects: 45
Study: 26031786

Group type: EXPERIMENTAL
Intervention: Medical alert device
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control
Number of subjects: 265
Study: 23930635

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive Adper Prompt L-Pop
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional phosphoric acid-etching technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both techniques (self-etching and conventional)
Number of subjects: 45
Study: 21285943

Group type: EXPERIMENTAL
Intervention: Group treatment (15 sessions separately for children and parents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine counselling (two appointments for children)
Number of subjects: 0
Study: 18811602

Group type: EXPERIMENTAL
Intervention: 10 mg of isotretinoin thrice a week for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg of isotretinoin thrice a week for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg and 20 mg of isotretinoin
Number of subjects: 30
Study: 17350990

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir + saquinavir (400/100 mg + 800 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: lopinavir/ritonavir + zidovudine/lamivudine (400/100 mg + 150/300 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir + saquinavir (600 or 800 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: lopinavir/ritonavir + zidovudine/lamivudine
Number of subjects: 30
Study: 14705221

Group type: EXPERIMENTAL
Intervention: Culturally sensitive cholesterol lowering dietary program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 11883998

Group type: EXPERIMENTAL
Intervention: rhGH (13 IU/m(2) for 4 days) + glutamine-free TPN
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhGH (13 IU/m(2) for 4 days) + glutamine-enriched TPN (7 g GLN/m(2)/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glutamine-enriched TPN (without rhGH)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GH treated groups
Number of subjects: 31

Group type: COMPARATOR
Intervention: Group III (glutamine-enriched TPN without rhGH)
Number of subjects: 31
Study: 9630144

Group type: EXPERIMENTAL
Intervention: Mixed endurance and calisthenic/strength activities performed at a rapid pace three times weekly for 12 weeks
Number of subjects: 20
Study: 8166318

Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dim red light therapy (500 lux for 30 min/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day) in patients with seasonal bulimia
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day) in patients with nonseasonal bulimia
Number of subjects: 17
Study: 3284292

Group type: EXPERIMENTAL
Intervention: Captopril (12.5‐25 mg b.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29514268

Group type: EXPERIMENTAL
Intervention: TARGET workshop
Number of subjects: 152
Study: 28537969

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (levo group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline 0.9% solution (saline group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (levo vs saline)
Number of subjects: 19
Study: 26625505

Group type: EXPERIMENTAL
Intervention: Co-payment reduction from $8 to $0 per medication per month for antihypertensive prescriptions
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Computerized behavioral intervention (CBI)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Both co-pay reduction and CBI
Number of subjects: 479

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 479
Study: 23445666

Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Classical music (neutral intervention)
Number of subjects: 22